DavidPSteensmaMDFACP

Oncology • Cambridge, MA

Hematologic Oncology

Global Head of Hematology, Novartis Institutes for BioMedical Research

Join to view full profile

Dr. Steensma is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Steensma's full profile

Already have an account?

Office
250 Massachusetts Ave
Cambridge, MA 02139
Phone+1 617-871-8000

Education & Training

University of OxfordNA, Molecular Hematology, 2002 - 2004
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1999 - 2002
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1996 - 1999
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1996
Calvin UniversityBS, Physics & Astronomy, 1988 - 1992

Certifications & Licensure

MA State Medical License 2009 - 2026
FL State Medical License 2016 - 2018
MN State Medical License 1997 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor or National Top Doctor Castle Connolly
Boston Magazine Top Doctors - Medical Oncology, 2017
Leadership in Science Aplastic Anemia & MDS International Foundation, 2016
Applications Award International Society for Systems Biology, 2015
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Epoetin Alfa in Treating Anemia in Patients With Solid Tumors Start of enrollment: 2003 Jun 01
Completed
Phase 3
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Start of enrollment: 2013 Feb 20
Completed
Phase 1, Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Start of enrollment: 2014 Oct 28
Completed
Phase 1, Phase 2
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Start of enrollment: 2015 Nov 24
Active, not recruiting
Phase 2, Phase 3
Tipifarnib in Subjects With Myelodysplastic Syndromes Start of enrollment: 2016 May 01
Terminated
Phase 2
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2016 Sep 20
Completed
Phase 2
A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Start of enrollment: 2016 Oct 06
Terminated
Phase 1
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Start of enrollment: 2017 May 18
Completed
Phase 1, Phase 2
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Start of enrollment: 2019 Aug 28
Active, not recruiting
Phase 2
APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Start of enrollment: 2019 Jan 11
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

266 citations
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
David A. Sallman, Amy E. DeZern, Guillermo Garcia-Manero, David P. Steensma, Gail J. Roboz
Journal of Clinical Oncology. 2021-01-15
302 citations
Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation
Rafael Bejar, Kristen E. Stevenson, Bennett A. Caughey, R. Coleman Lindsley, Brenton G. Mar
Journal of Clinical Oncology. 2014-09-01
38 citations
Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database.
Sean A. Fletcher, Angel M. Cronin, Amer M. Zeidan, Oreofe O. Odejide, Steven D. Gore
Cancer. 2016-04-15

Journal Articles

The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk Factor
Robert Sidlow, Amy E Lin, David P Steensma, Benjamin L Ebert, JAMA Cardiology
The Phenotypic Spectrum of Germline YARS2 Variants: From Isolated Sideroblastic Anemia to Mitochondrial Myopathy, Lactic Acidosis and Sideroblastic Anemia 2
Matthew M Heeney, Gregory A Hale, David P Steensma, Mark D Fleming, Colin A Sieff, Lee M Hilliard, Sylvia S Bottomley, Janet L Kwiatkowski, Haematologica

Abstracts/Posters

Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) ...
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Sleep Disturbance Among Patients with Myelodysplastic Syndromes and Acute Leukemia
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
I-Care for MDS: Development of Guidelines-Based Indicators for Appropriate Care in Adult Patients with Myelodysplastic Syndromes
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapse...
David P. Steensma, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
David P. Steensma, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Join now to see all

Lectures

How to Interpret Next Generation Sequencing Panels in Patients with CHIP and Hematolymphoid Neoplasms
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS)
60th American Society of Hematology Annual Meeting - 12/2/2018
The Molecular Maelstrom of Myelodysplastic Syndromes (MDS)
60th American Society of Hematology Annual Meeting - 12/1/2018
Treating Myelodysplastic Syndromes: From Clonal Hematopoiesis to Almost Acute Myeloid Leukemia
60th American Society of Hematology Annual Meeting - 12/1/2018
Quality of Life and Psychological Distress in Patients with Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Self-Care: Survival Tips for When It Seems Like You're a Cog in a Broken Machine
60th American Society of Hematology Annual Meeting - 11/30/2018
Proposals for Revised IWG 2018 Hematological Response Criteria in Patients with MDS Included in Clinical Trials
Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, San Diego, California - 12/9/2011
Proposals for Revised IWG 2018 Hematological Response Criteria in Patients with MDS Included in Clinical Trials
American Society of Hematology (ASH), Atlanta, Georgia - 1/27/2012
Building a Clinical Research Team
Trainee Day, American Society of Hematology 2017 Annual Meeting - 12/7/2017
Albert H. Owens, Jr. Memorial Lectureship
Johns Hopkins University - Sidney Kimmel Cancer Center - 9/2017
Cancer Medicine and Hematology 2017
Boston, MA - 9/2017
Adair Memorial Lectureship
Houston Methodist Hospital - 5/2017
2016 Highlights of the American Society of Hematology Annual Meeting
Toronto, New York, Atlanta, Brisbane, Porto Alegre - 2016
Join now to see all

Other

Proposals for Revised IWG 2018 Hematological Response Criteria in Patients with MDS Included in Clinical Trials
David Steensma, MD, Blood
https://www.doximity.com/articles/6ad4584e-b8e8-47df-9d1a-dfd99ada3c29
UpToDate, Wolters Kluwer Health - 2013-03-04

Authored Content

Editor’s Corner: The Zoombie ApocalypseJuly 2020
The Clinical Challenge of Clonal Hematopoiesis, a Newly Recognized Cardiovascular Risk FactorMay 2020

Press Mentions

Unfiltered: The Insurance Denials Most Frustrating to PhysiciansApril 21st, 2023
ASH Minority Recruitment Initiative Seeks Mentors, ASH Joins in Support of the Federal Safe Step Act, and MoreJune 2nd, 2021
End of an Era: The Medical Community Responds to the Elimination of Step 2 CSFebruary 3rd, 2021
Join now to see all

Grant Support

Edward P. Evans Center for Myelodysplastic Syndromes at Dana-FarberEdward P. Evans Foundation2019–2024
Pathogenesis of Myeloid NeoplasiaJames and Lois Champy Foundation2015–Present
MDS Clinical Research ConsortiumEdward P. Evans Foundation - AA&MDS IF2012–Present
SPORE in Myeloid MalignanciesNational Cancer Institute2017–2022
Targeting Stem Cells in Acute LeukemiasV Foundation2013–2018

Committees

Member, American Society of Hematology Committee on Publications 2017 - Present
Scientific Advisory Board / Grant Reviewer, Joseph P. Dresner Foundation 2016 - Present
Member, American Board of Internal Medicine Hematology Examination Committee 2016 - Present
Scientific Advisory Board / Grant Reviewer, Edward P. Evans Foundation 2015 - Present
Member, American Society of Hematology Task Force on Precision Medicine 2015 - Present
Member, American Society of Hematology Committee on Educational Affairs 2013 - Present
Board of Directors, Myelodysplastic Syndromes Foundation 2009 - 2013
Oncology Drugs Advisory Committee, Food and Drug Administration 2007 - 2012
Medical Advisory Board, Aplastic Anemia & Myelodysplastic Syndromes International Foundation